AdaptHealth Corp. Stock: price and insider trades · United States · SEC (Form 4)

About AdaptHealth Corp.

AdaptHealth Corp. (ticker: AHCO) is a United States-listed healthcare company traded on the NASDAQ, not the NYSE. Headquartered in Conshohocken, Pennsylvania, United States, the company has built itself into a national player in home-based healthcare solutions, with a core focus on home medical equipment, medical supplies, and related services. Its business model is centered on supporting patients after hospital discharge or following a physician referral, helping extend care into the home while improving adherence, convenience, and overall cost efficiency. ([adapthealth.com](https://adapthealth.com/2026/02/24/adapthealth-corp-announces-fourth-quarter-and-full-year-2025-results-and-provides-2026-financial-guidance/?utm_source=openai)) AdaptHealth reports four business segments that align with its product categories: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. This structure gives the company exposure to several durable healthcare demand pools, including sleep apnea and respiratory therapy, diabetes care and glucose monitoring, and broader home wellness and care-at-home solutions. The company’s portfolio includes continuous glucose monitoring devices, insulin pumps, respiratory devices and supplies, and other home-based medical products and services. Management positions AdaptHealth as a nationwide network of trusted medical equipment providers, combining clinically focused products, technology, and patient support. ([adapthealth.com](https://adapthealth.com/investorrelations/corporate-profile/?utm_source=openai)) From a competitive standpoint, AdaptHealth operates in a highly fragmented but competitive market, facing national and regional rivals such as Owens & Minor, Lincare, Rotech, Cardinal Health, and Quipt Home Medical, among others. Its strategic edge lies in scale, geographic reach, and the ability to serve multiple product categories through a broad operational platform. As of year-end 2025, the company said it served approximately 4.3 million patients annually across 48 states, underscoring its broad U.S. footprint and national distribution network. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1725255/000162828025007740/ahco-20241231.htm?utm_source=openai)) Recent developments have centered on balance-sheet repair and operational simplification. In 2025, the company completed the sale of certain non-core infusion assets to help reduce debt, and in November 2025 S&P Global Ratings upgraded the issue-level rating on AdaptHealth’s senior unsecured debt. In February 2026, AdaptHealth reported full-year 2025 results and issued 2026 guidance, highlighting operating cash flow growth, record patient census in several categories, and the acquisition of a leading HME provider in Hawaii, which expanded the company’s footprint to its 48th state. For investors, AHCO is therefore a healthcare-at-home name with meaningful scale and structural tailwinds, but one that remains sensitive to reimbursement dynamics, patient volumes, and execution on its capital structure. ([adapthealth.com](https://adapthealth.com/blogs/latest-news/adapthealth-corp-closes-transaction-to-dispose-of-certain-home-infusion-assets-and-reduces-debt?utm_source=openai))